Clinical Vignette Series: 37th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Activity Overview

In Clinical Vignette Series: 37th Annual Chemotherapy Foundation Symposium (CFS^®): Innovative Cancer Therapy for Tomorrow^®, oncology thought leaders address clinical challenges faced by community oncologists, like you, and offer their insight and commentary on the clinical application of new data and advances. This interactive, online activity features a series of case-based vignettes, self-reflection questions, and brief audio-video clips in which the program faculty share their approaches and answer other related questions. This activity touches on established and emerging standards of care in multiple myeloma, as well as cancers of the breast, lung, kidney, pancreas, and liver. It is based on content presented at the 2019 CFS^® meeting. This annual gathering has a longstanding history of providing education, guidance, perspectives, and solutions to practicing oncologists. Delivering state-of-the-art cancer care requires incorporation of new clinical advances and data into practice. Across all cancer types, improvements in patient outcomes are being driven by novel approaches in testing, systemic therapy, targeted therapy and immunotherapies, and combination strategies. This online activity provides an unparalleled opportunity to learn new methods of optimizing and personalizing care for your patients with cancer.

Benefits of Participating

• Incorporate the latest clinical data and evidence-based strategies into your practice
• Learn experts’ viewpoints on areas of clinical uncertainty

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie Inc.; AstraZeneca; Athenex; Celgene Corporation; Daiichi Sankyo, Inc.; Eisai; Exelixis, Inc.; Genomic Health; Incyte Corporation; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Pfizer; Regeneron; Sanofi Genzyme; Seattle Genetics, Inc.; and Taiho Oncology, Inc.

Target Audience

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists involved in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Review key testing strategies across tumor types for identification of tumor markers for prognostic/predictive assessment and selection of appropriate treatment.
• Recognize practice-changing results to inform improved diagnosis, treatment, and adverse event management across solid and liquid tumors.
• Identify ways of translating novel evidence-based treatment strategies using immunotherapeutic, targeted treatment, and chemotherapeutic treatment strategies into clinical practice.
• Learn strategies for promoting multidisciplinary best practices in the proactive management of treatment-related toxicities.
• Analyze practice-changing evidence presented at major conferences and apply these findings to improve the treatment of patients with cancer.

Faculty, Staff, and Planners’ Disclosures

Faculty

Kevin Kalinsky, MD, MS
Medical Oncologist, Division of Hematology/Oncology
Herbert Irving Associate Professor of Medicine
Columbia University Irving Medical Center
New York, NY

Disclosures: Grant Research Support: Institutional support: Incyte, Genentech, Eli-Lilly, Pfizer, Calithera Biosciences, Acetylon, Seattle Genetics, Amgen, Zeno Pharmaceuticals, CytomX Therapeutics; Commercial Employee Role: Array BioPharma, Pfizer

Wasif M. Saif, MD, MBBS
Deputy Physician-in-Chief and Director
Director, Medical Oncology
Northwell Health Cancer Institute
Professor, The Center for Health Innovations and Outcome Research
The Feinstein Institute for Medical Research
Professor, Medical Oncology
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Lake Success, NY

Disclosures: Grant Research Support: Tesaro, Lexicon, Yivia, Celgene, Taiho, Pharmacyclic, Nanocam, Ipsen; Speakers Bureau: Genetech, Ipsen, Lexicon, Celgene.

Marc J. Braunstein, MD, PhD
Assistant Professor, Department of Medicine
NYU Long Island School of Medicine
NYU Langone Health
Mineola, NY

Disclosures: Grant Research Support: Janssen, Celgene, uBiome; Other: Advisory Boards: Amgen, Takeda, AstraZeneca, Celgene, Janssen, Verastem.

Alexander E. Drilon, MD
Clinical Director, Early Drug Development Service
Associate Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: Medscape, OncLive, PeerVoice, Physicians’ Education Resource, Tyra Biosciences, Targeted Oncology, MORE Health, Research to Practice, Foundation Medicine, PeerView, AstraZeneca, Genentech/Roche, Bayer, Ignyta, Loxo, TP Therapeutics, Pfizer, Blueprint Medicines, Genentech/Roche, Takeda, Helsinn Therapeutics, BeiGene, Hengrui Therapeutics, Exelixis, Wolters Kluwer, PharmaMar.

Robert J. Motzer, MD
Jack and Dorothy Byrne Chair in Clinical Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Bristol-Myers Squibb, Pfizer, Eisai, Exelixis, Novartis; Consultant: Pfizer, Novartis, Eisai, Exelixis.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.